RB1 and neoplasm: On the other hand, since RB1 cannot be considered as a therapeutic target, genes involved in RB1‐deficiency‐related aberrant signals and pathways were considered as actionable targets, such as transcriptional targets and tumor microenvironment [15, 16, 17].